FDA Approves TUXARIN — Mainpointe Pharmaceuticals

Mainpointe Pharmaceuticals announced Tuesday that the FDA has approved TUXARIN (codeine phosphate and chlorpheniramine maleate), introducing a new branded option to the steadily expanding generic market for opioid-containing combination cold medicines. This approval intensifies competition in the OTC opioid sector and allows Mainpointe to capitalize on the growing demand for comprehensive therapy for acute respiratory conditions during the flu and cold season.